Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | CNR1 | P21554 | 4/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.38 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.38 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.38 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.38 |
| ▸ | NAAA | Q02083 | 1/20 | 0.36 |
| ▸ | SELP | P16109 | 1/20 | 0.36 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.36 |
| ▸ | FAAH | O00519 | 1/20 | 0.36 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
| ▸ | BLM | P54132 | 1/20 | 0.36 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7583332 | 0.98 | DNM1 (0.39) | DNM1ALDH1A1MEN1KMT2AUSP2 | |
| Oxalic Acid SCHEMBL9795343 | 0.94 | DNM1 (0.37) | DNM1ALDH1A1MEN1KMT2AUSP2 | |
| SCHEMBL4578889 | 0.86 | DNM1 (0.46) | DNM1ALDH1A1MEN1KMT2ACNR1 | |
| SCHEMBL12565683 | 0.86 | MEN1 (0.39) | DNM1ALDH1A1MEN1KMT2AUSP2 | |
| SCHEMBL8741153 | 0.83 | MEN1 (0.48) | DNM1ALDH1A1MEN1KMT2ANAAA | |
| SCHEMBL1827225 | 0.83 | MEN1 (0.54) | DNM1ALDH1A1MEN1KMT2ANAAA | |
| SCHEMBL20710636 | 0.82 | DNM1 (0.59) | DNM1ALDH1A1MEN1KMT2ALMNA | |
| SCHEMBL2127728 | 0.81 | MCL1 (0.48) | DNM1MEN1KMT2AMAPTCNR1 | |
| SCHEMBL8956453 | 0.81 | HDAC1 (0.40) | DNM1MEN1KMT2AMAPT | |
| SCHEMBL20801640 | 0.81 | MEN1 (0.40) | DNM1ALDH1A1MEN1KMT2AUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1951686-B1 | QUINAZOLINE DERIVATIVES AS A MULTIPLEX INHIBITOR AND METHOD FOR THE PREPARATION THEREOF | HANMI PHARM IND CO LTD (KR) | 2013-04-03 | — | — | EP | claimed |
| US-20080318950-A1 | Quinazoline Derivatives as a Multiplex Inhibitor and Method For the Preparation Thereof | HANMI PHARM. CO., LTD (KR) | 2008-12-25 | — | — | US | claimed |
| EP-1951686-A1 | QUINAZOLINE DERIVATIVES AS A MULTIPLEX INHIBITOR AND METHOD FOR THE PREPARATION THEREOF | Hanmi Pharm. Co., Ltd. (KR) | 2008-08-06 | — | — | EP | claimed |
| WO-2007055514-A1 | QUINAZOLINE DERIVATIVES AS A MULTIPLEX INHIBITOR AND METHOD FOR THE PREPARATION THEREOF | HANMI PHARM. CO., LTD. (KR) | 2007-05-18 | — | — | WO | claimed |
| US-8846699-B2 | Quinazoline derivatives as a multiplex inhibitor and method for the preparation thereof | HANMI PHARM. CO., LTD. (KR) | 2014-09-30 | — | — | US | disclosed |
| EP-1951686-B1 | QUINAZOLINE DERIVATIVES AS A MULTIPLEX INHIBITOR AND METHOD FOR THE PREPARATION THEREOF | HANMI PHARM IND CO LTD (KR) | 2013-04-03 | — | — | EP | disclosed |
| EP-2307385-A1 | 2 -ARYLAMINOQUINAZOLINES FOR TREATING PROLIFERATIVE DISEASES | Novartis AG (CH) | 2011-04-13 | — | — | EP | disclosed |
| US-20100121052-A1 | Novel compounds for treating proliferative diseases | JAIN RAMA | 2010-05-13 | — | — | US | disclosed |
| WO-2009153313-A1 | 2 -ARYLAMINOQUINAZOLINES FOR TREATING PROLIFERATIVE DISEASES | NOVARTIS AG (CH) | 2009-12-23 | — | — | WO | disclosed |
| US-20080318950-A1 | Quinazoline Derivatives as a Multiplex Inhibitor and Method For the Preparation Thereof | HANMI PHARM. CO., LTD (KR) | 2008-12-25 | — | — | US | disclosed |
| EP-1951686-A1 | QUINAZOLINE DERIVATIVES AS A MULTIPLEX INHIBITOR AND METHOD FOR THE PREPARATION THEREOF | Hanmi Pharm. Co., Ltd. (KR) | 2008-08-06 | — | — | EP | disclosed |
| WO-2007055514-A1 | QUINAZOLINE DERIVATIVES AS A MULTIPLEX INHIBITOR AND METHOD FOR THE PREPARATION THEREOF | HANMI PHARM. CO., LTD. (KR) | 2007-05-18 | — | — | WO | disclosed |
| WO-1993023402-A1 | 3-AZETIDINYLTHIO-CARBAPENEME DERIVATIVES, THEIR PREPARATION AND USE AS ANTIMICROBIAL AGENTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1993-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100121052-A1 | Novel compounds for treating proliferative diseases | PDK1, PDK2, PDK3 | DNM1 710/4885ALDH1A1 2281/4885MEN1 1354/4885 |
| US-20080318950-A1 | Quinazoline Derivatives as a Multiplex Inhibitor and Method For the Preparation Thereof | ABL1, JAK1, BTK | DNM1 1616/4885ALDH1A1 3502/4885MEN1 1070/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.